UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 138

Sortiert nach

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data

Translational psychiatry, 2020-08, Vol.10 (1), p.276-276, Article 276

2020

Volltextzugriff (PDF)

Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol

Frontiers in psychiatry, 2022-05, Vol.13, p.889572-889572

2022

Volltextzugriff (PDF)

Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients

Frontiers in neuroscience, 2020-05, Vol.14, p.484-484

2020

Volltextzugriff (PDF)

Cortico-cognition coupling in treatment resistant schizophrenia

NeuroImage clinical, 2022-01, Vol.35, p.103064-103064, Article 103064

2022

Volltextzugriff (PDF)

Disruption of Neurogenesis on Gestational Day 17 in the Rat Causes Behavioral Changes Relevant to Positive and Negative Schizophrenia Symptoms and Alters Amphetamine-Induced Dopamine Release in Nucleus Accumbens

Neuropsychopharmacology, 2004-11, Vol.29 (11), p.2052-2064

2004

Volltextzugriff (PDF)

Cognitive Deficits Caused by Late Gestational Disruption of Neurogenesis in Rats: a Preclinical Model of Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2005-02, Vol.30 (2), p.250-260

2005

Volltextzugriff (PDF)

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users

Cochrane database of systematic reviews, 2018-03, Vol.3 (3), p.CD011481

2018

Volltextzugriff (PDF)

Using computer vision of facial expressions to assess symptom domains and treatment response in antipsychotic‐naïve patients with first‐episode psychosis

Acta psychiatrica Scandinavica, 2024-08

2024

Volltextzugriff (PDF)

Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra‐high risk for psychosis

Human brain mapping, 2019-12, Vol.40 (18), p.5185-5201

2019

Volltextzugriff (PDF)

Clinical response to treatment with a partial dopamine agonist is related to changes in reward processing

Psychiatry research, 2023-08, Vol.326, p.115308-115308, Article 115308

2023

Volltextzugriff (PDF)

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis

Psychological medicine, 2020-10, Vol.50 (13), p.2182-2193

2020

Volltextzugriff (PDF)

Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients

Psychological medicine, 2019-12, Vol.49 (16), p.2754-2763

2019

Volltextzugriff (PDF)

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

BMC psychiatry, 2021-08, Vol.21 (1), p.1-404, Article 404

2021

Volltextzugriff (PDF)

Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra‐high risk for psychosis

Acta psychiatrica Scandinavica, 2021-11, Vol.144 (5), p.448-463

2021

Volltextzugriff (PDF)

Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.162-171

2017

Volltextzugriff (PDF)

High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10: A randomized clinical trial

The American journal of clinical nutrition, 2024-02, Vol.119 (2), p.362

2024

Volltextzugriff (PDF)

Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients

Psychological medicine, 2019-04, Vol.49 (5), p.868-875

2019

Volltextzugriff (PDF)

Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication

Neuropsychopharmacology (New York, N.Y.), 2019-05, Vol.44 (6), p.1062-1067

2019

Volltextzugriff (PDF)

Reward disturbances in antipsychotic-naïve patients with first-episode psychosis and their association to glutamate levels

Psychological medicine, 2023-03, Vol.53 (4), p.1629-1638

2023

Volltextzugriff (PDF)

White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosis

Frontiers in human neuroscience, 2022-10, Vol.16, p.1029149-1029149

2022

Volltextzugriff (PDF)

Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis

Schizophrenia research, 2021-11, Vol.237, p.192-201

2021

Volltextzugriff (PDF)

Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients

Neuropsychopharmacology (New York, N.Y.), 2014-12, Vol.39 (13), p.3000-3008

2014

Volltextzugriff (PDF)

Clonidine Normalizes Sensorimotor Gating Deficits in Patients With Schizophrenia on Stable Medication

Schizophrenia bulletin, 2013-05, Vol.39 (3), p.684-691

2013

Volltextzugriff (PDF)

Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nation-wide twin study

Psychological medicine, 2022-04, Vol.52 (6), p.1101-1114

2022

Volltextzugriff (PDF)

P50 Suppression and Its Neural Generators in Antipsychotic-Naïve First-Episode Schizophrenia Before and After 6 Months of Quetiapine Treatment

Schizophrenia bulletin, 2013-03, Vol.39 (2), p.472-480

2013

Volltextzugriff (PDF)

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(130)

Publikationsform

Artikel
(137)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(94)
Science & Technology
(94)
Psychiatry
(80)
Humans
(69)
Schizophrenia
(67)
Male
(51)
Adult
(49)
Neurosciences & Neurology
(43)
Neurosciences
(40)
Female
(36)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Schizophrenia - Drug Therapy
(27)
Antipsychotics
(25)
Psychology. Psychoanalysis. Psychiatry
(25)
Psychotropic Drugs
(23)
Young Adult
(23)
Pharmacology & Pharmacy
(22)
Psychopathology. Psychiatry
(22)
Schizophrenia - Physiopathology
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data

Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol

Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients

Cortico-cognition coupling in treatment resistant schizophrenia

Disruption of Neurogenesis on Gestational Day 17 in the Rat Causes Behavioral Changes Relevant to Positive and Negative Schizophrenia Symptoms and Alters Amphetamine-Induced Dopamine Release in Nucleus Accumbens

Cognitive Deficits Caused by Late Gestational Disruption of Neurogenesis in Rats: a Preclinical Model of Schizophrenia

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users

Using computer vision of facial expressions to assess symptom domains and treatment response in antipsychotic‐naïve patients with first‐episode psychosis

Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra‐high risk for psychosis

Clinical response to treatment with a partial dopamine agonist is related to changes in reward processing

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis

Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra‐high risk for psychosis

Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10: A randomized clinical trial

Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients

Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication

Reward disturbances in antipsychotic-naïve patients with first-episode psychosis and their association to glutamate levels

White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosis

Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis

Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients

Clonidine Normalizes Sensorimotor Gating Deficits in Patients With Schizophrenia on Stable Medication

Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nation-wide twin study

P50 Suppression and Its Neural Generators in Antipsychotic-Naïve First-Episode Schizophrenia Before and After 6 Months of Quetiapine Treatment

Suchergebnisse filtern